1Rigg A, Cunningham D, Gore M, et al. A Phase Ⅰ / Ⅱ study of leucovor- in, carboplatin and 5-fluorouraeil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocareinomas. Br J Cancer. 1997,75( 1 ): 101-105.
2Macdonald AG, Nicolson MC, Samuel LM, et al. A Phase Ⅱ study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. Br J Cancer.2002,86(8): 1 238-1 242.
3Le Chevalier T, Cvitkovic E, Caille P, et al. Early metastatic cancer of unknown primary origin at presentation A clinical study of 302 consecutive autopsied patients. Arch Intern Med. 1988, 148(9) :2 035-2 039.
4Lortholary A, Abadie-Lacourtoisie S, Guerin O , et al. Cancers of unknown origin:311 cases. Bull Cancer,2001,88(6) :619-627.
5Culine S, Gazagne L, Ychou M, et al. Carcinoma of unknown primary site. Apropos of 100 patients treated at the Montpellier regional center of cancer prevaention. Rev Med Interne, 1998, 19(10) :713-719.
6Milliken ST, Tattersall MH, Woods RL, et al. Metastatic adenocareinoma of unknown primary site. A randomized study of two combination chemtherapyregimens. Eur J Cancer Clin Oncol, 1987,23( 11 ): 1 645-1 648.
7Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNAcontent and survival. Eur J Cancer Clin Oncol, 1985,21 (2): 185-189.
8Hainsworth JD, Erland JB, Kalman LA, et al. Carcinoma of unknown primary site: treatment with l-hour paclitaxel, carboplatin, and extendedschedule etoposide. J Clin Oncol, 1997,15(6) :2 385-2 393.
9Greeo FA, Hainsworth JD. Poorly differentiated carcinoma or adenocarcinoma of undnown primary site: long-term results with cisplatin-based chemotherapy. Semin Oncol, 1994,21 (5 Suppl 12) :77-82.
10Greco FA, Johnson DH, Hainsworth JD. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated careinoma of unknown primary site. Semin Oncol, 1992, 19 (6 Suppl 13 ): 14-18.
